Moflaxa (Moxifloxacin)

Moxifloxacin, the active ingredient in Moflaxa, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and skin and soft‑tissue infections in adults.

GNH USA supplies Moflaxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑supported distribution across EU and global markets. Customers benefit from reliable supply chains and comprehensive technical support.

Moxifloxacin is a fluoroquinolone antibacterial used to treat infections of the respiratory tract and skin. - Community‑acquired pneumonia: effective in eliminating the typical bacterial pathogens responsible for acute lung infection. - Acute bacterial sinusitis: reduces sinus inflammation by eradicating causative bacteria. - Acute bacterial exacerbation of chronic bronchitis: helps restore airway function by targeting bacterial overgrowth. - Skin and soft‑tissue infections: combats Gram‑positive and Gram‑negative organisms in cellulitis, abscesses and wound infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that are usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or swelling, especially in the Achilles. - QT interval prolongation: cardiac rhythm changes that may lead to arrhythmia. - Severe hypersensitivity: anaphylactic reactions with swelling, hives, or breathing difficulty. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - Liver enzyme elevation: significant increase in transaminases indicating hepatic stress.

When prescribing Moxifloxacin, clinicians should consider several precautionary measures to minimize risk. - Assess renal function: adjust use in patients with severe impairment. - Review cardiac history: avoid in individuals with known QT prolongation. - Evaluate tendon health: caution in patients with recent tendon injury or steroid use. - Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. - Use with caution in the elderly: increased susceptibility to adverse events. - Avoid concomitant use with other fluoroquinolones: increased risk of tendon toxicity. - Store at ambient temperature: keep below 25°C in original packaging, protected from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of the antibiotic. - Warfarin: may enhance anticoagulant effect and increase bleeding risk. - Cyclosporine: can raise moxifloxacin plasma levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system stimulation. - Corticosteroids: combined use may heighten tendon rupture risk. - Diabetes medications (e.g., sulfonylureas): may cause hypoglycemia due to altered glucose metabolism.